世界の非アルコール性脂肪性肝炎（NASH）治療市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size, Status and Forecast 2021-2027

• レポートコード：QFJ1-4586 • 出版社/出版日：QYResearch / 2021年6月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、99ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療

• 販売価格（消費税別）

Single User	￥577,200 (USD3,900)	▷ お問い合わせ
Multi User	￥865,800 (USD5,850)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

QYResearch社発行の本調査レポートでは、非アルコール性脂肪性肝炎（NASH）治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（保険適用外、治療）、用途別市場規模（病院薬局、オンラインプロバイダー、小売薬局）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、企業情報などをまとめております。 ・市場概要 ・非アルコール性脂肪性肝炎（NASH）治療の市場動向 ・企業の競争状況、市場シェア ・非アルコール性脂肪性肝炎（NASH）治療の種類別市場規模と予測2016-2027（保険適用外、治療） ・非アルコール性脂肪性肝炎（NASH）治療の用途別市場規模と予測2016-2027（病院薬局、オンラインプロバイダー、小売薬局） ・非アルコール性脂肪性肝炎（NASH）治療の北米市場規模2016-2027（アメリカ、カナダ） ・非アルコール性脂肪性肝炎（NASH）治療の欧州市場規模2016-2027（ドイツ、フランス、イギリス等） ・非アルコール性脂肪性肝炎（NASH）治療のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・非アルコール性脂肪性肝炎（NASH）治療の中南米市場規模2016-2027（メキシコ、ブラジル） ・非アルコール性脂肪性肝炎（NASH）治療の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Allergan Plc (Tobira)、Bristol Myers Squibb、Galmed Pharmaceuticals、Genfit SA、Gilead Sciences, Inc.、Intercept Pharmaceuticals, Inc.、Zydus Cadila） ・結論

Market Analysis and Insights: Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market
The global Non-Alcoholic Steatohepatitis (NASH) Treatment market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Non-Alcoholic Steatohepatitis (NASH) Treatment market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Non-Alcoholic Steatohepatitis (NASH) Treatment market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Non-Alcoholic Steatohepatitis (NASH) Treatment market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Non-Alcoholic Steatohepatitis (NASH) Treatment market.

Global Non-Alcoholic Steatohepatitis (NASH) Treatment Scope and Market Size
Non-Alcoholic Steatohepatitis (NASH) Treatment market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Non-Alcoholic Steatohepatitis (NASH) Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Off-Label
Therapeutic

Segment by Application
Hospital Pharmacy
Online Provider
Retail Pharmacy

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Allergan Plc (Tobira)
Bristol Myers Squibb
Galmed Pharmaceuticals
Genfit SA
Gilead Sciences, Inc.
Intercept Pharmaceuticals, Inc.
Zydus Cadila

レポート目次

---

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Off-Label
1.2.3 Therapeutic
1.3 Market by Application
1.3.1 Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospital Pharmacy
1.3.3 Online Provider
1.3.4 Retail Pharmacy
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market Perspective (2016-2027)
2.2 Non-Alcoholic Steatohepatitis (NASH) Treatment Growth Trends by Regions
2.2.1 Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Non-Alcoholic Steatohepatitis (NASH) Treatment Historic Market Share by Regions (2016-2021)
2.2.3 Non-Alcoholic Steatohepatitis (NASH) Treatment Forecasted Market Size by Regions (2022-2027)
2.3 Non-Alcoholic Steatohepatitis (NASH) Treatment Industry Dynamic
2.3.1 Non-Alcoholic Steatohepatitis (NASH) Treatment Market Trends
2.3.2 Non-Alcoholic Steatohepatitis (NASH) Treatment Market Drivers
2.3.3 Non-Alcoholic Steatohepatitis (NASH) Treatment Market Challenges
2.3.4 Non-Alcoholic Steatohepatitis (NASH) Treatment Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Non-Alcoholic Steatohepatitis (NASH) Treatment Players by Revenue
3.1.1 Global Top Non-Alcoholic Steatohepatitis (NASH) Treatment Players by Revenue (2016-2021)
3.1.2 Global Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue Market Share by Players (2016-2021)
3.2 Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue
3.4 Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market Concentration Ratio
3.4.1 Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue in 2020
3.5 Non-Alcoholic Steatohepatitis (NASH) Treatment Key Players Head office and Area Served
3.6 Key Players Non-Alcoholic Steatohepatitis (NASH) Treatment Product Solution and Service
3.7 Date of Enter into Non-Alcoholic Steatohepatitis (NASH) Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Non-Alcoholic Steatohepatitis (NASH) Treatment Breakdown Data by Type
4.1 Global Non-Alcoholic Steatohepatitis (NASH) Treatment Historic Market Size by Type (2016-2021)
4.2 Global Non-Alcoholic Steatohepatitis (NASH) Treatment Forecasted Market Size by Type (2022-2027)

5 Non-Alcoholic Steatohepatitis (NASH) Treatment Breakdown Data by Application
5.1 Global Non-Alcoholic Steatohepatitis (NASH) Treatment Historic Market Size by Application (2016-2021)
5.2 Global Non-Alcoholic Steatohepatitis (NASH) Treatment Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size (2016-2027)
6.2 North America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Type
6.2.1 North America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Type (2016-2021)
6.2.2 North America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Type (2022-2027)
6.2.3 North America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Type (2016-2027)
6.3 North America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Application
6.3.1 North America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Application (2016-2021)
6.3.2 North America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Application (2022-2027)
6.3.3 North America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Application (2016-2027)
6.4 North America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Country
6.4.1 North America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Country (2016-2021)
6.4.2 North America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada

7 Europe
7.1 Europe Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size (2016-2027)
7.2 Europe Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Type
7.2.1 Europe Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Type (2016-2021)
7.2.2 Europe Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Type (2022-2027)
7.2.3 Europe Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Type (2016-2027)
7.3 Europe Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Application
7.3.1 Europe Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Application (2016-2021)
7.3.2 Europe Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Application (2022-2027)
7.3.3 Europe Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Application (2016-2027)
7.4 Europe Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Country
7.4.1 Europe Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Country (2016-2021)
7.4.2 Europe Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size (2016-2027)
8.2 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Type
8.2.1 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Type (2016-2027)
8.3 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Application
8.3.1 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Application (2016-2027)
8.4 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Region
8.4.1 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size (2016-2027)
9.2 Latin America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Type
9.2.1 Latin America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Type (2016-2021)
9.2.2 Latin America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Type (2022-2027)
9.2.3 Latin America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Type (2016-2027)
9.3 Latin America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Application
9.3.1 Latin America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Application (2016-2021)
9.3.2 Latin America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Application (2022-2027)
9.3.3 Latin America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Application (2016-2027)
9.4 Latin America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Country
9.4.1 Latin America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Country (2016-2021)
9.4.2 Latin America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size (2016-2027)
10.2 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Type
10.2.1 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Type (2016-2027)
10.3 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Application
10.3.1 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Application (2016-2027)
10.4 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Country
10.4.1 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Allergan Plc (Tobira)
11.1.1 Allergan Plc (Tobira) Company Details
11.1.2 Allergan Plc (Tobira) Business Overview
11.1.3 Allergan Plc (Tobira) Non-Alcoholic Steatohepatitis (NASH) Treatment Introduction
11.1.4 Allergan Plc (Tobira) Revenue in Non-Alcoholic Steatohepatitis (NASH) Treatment Business (2016-2021)
11.1.5 Allergan Plc (Tobira) Recent Development
11.2 Bristol Myers Squibb
11.2.1 Bristol Myers Squibb Company Details
11.2.2 Bristol Myers Squibb Business Overview
11.2.3 Bristol Myers Squibb Non-Alcoholic Steatohepatitis (NASH) Treatment Introduction
11.2.4 Bristol Myers Squibb Revenue in Non-Alcoholic Steatohepatitis (NASH) Treatment Business (2016-2021)
11.2.5 Bristol Myers Squibb Recent Development
11.3 Galmed Pharmaceuticals
11.3.1 Galmed Pharmaceuticals Company Details
11.3.2 Galmed Pharmaceuticals Business Overview
11.3.3 Galmed Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Treatment Introduction
11.3.4 Galmed Pharmaceuticals Revenue in Non-Alcoholic Steatohepatitis (NASH) Treatment Business (2016-2021)
11.3.5 Galmed Pharmaceuticals Recent Development
11.4 Genfit SA
11.4.1 Genfit SA Company Details
11.4.2 Genfit SA Business Overview
11.4.3 Genfit SA Non-Alcoholic Steatohepatitis (NASH) Treatment Introduction
11.4.4 Genfit SA Revenue in Non-Alcoholic Steatohepatitis (NASH) Treatment Business (2016-2021)
11.4.5 Genfit SA Recent Development
11.5 Gilead Sciences, Inc.
11.5.1 Gilead Sciences, Inc. Company Details
11.5.2 Gilead Sciences, Inc. Business Overview
11.5.3 Gilead Sciences, Inc. Non-Alcoholic Steatohepatitis (NASH) Treatment Introduction
11.5.4 Gilead Sciences, Inc. Revenue in Non-Alcoholic Steatohepatitis (NASH) Treatment Business (2016-2021)
11.5.5 Gilead Sciences, Inc. Recent Development
11.6 Intercept Pharmaceuticals, Inc.
11.6.1 Intercept Pharmaceuticals, Inc. Company Details
11.6.2 Intercept Pharmaceuticals, Inc. Business Overview
11.6.3 Intercept Pharmaceuticals, Inc. Non-Alcoholic Steatohepatitis (NASH) Treatment Introduction
11.6.4 Intercept Pharmaceuticals, Inc. Revenue in Non-Alcoholic Steatohepatitis (NASH) Treatment Business (2016-2021)
11.6.5 Intercept Pharmaceuticals, Inc. Recent Development
11.7 Zydus Cadila
11.7.1 Zydus Cadila Company Details
11.7.2 Zydus Cadila Business Overview
11.7.3 Zydus Cadila Non-Alcoholic Steatohepatitis (NASH) Treatment Introduction
11.7.4 Zydus Cadila Revenue in Non-Alcoholic Steatohepatitis (NASH) Treatment Business (2016-2021)
11.7.5 Zydus Cadila Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Off-Label
Table 3. Key Players of Therapeutic
Table 4. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 5. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 6. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Regions (2016-2021) & (US$ Million)
Table 7. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market Share by Regions (2016-2021)
Table 8. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 9. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market Share by Regions (2022-2027)
Table 10. Non-Alcoholic Steatohepatitis (NASH) Treatment Market Trends
Table 11. Non-Alcoholic Steatohepatitis (NASH) Treatment Market Drivers
Table 12. Non-Alcoholic Steatohepatitis (NASH) Treatment Market Challenges
Table 13. Non-Alcoholic Steatohepatitis (NASH) Treatment Market Restraints
Table 14. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue by Players (2016-2021) & (US$ Million)
Table 15. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market Share by Players (2016-2021)
Table 16. Global Top Non-Alcoholic Steatohepatitis (NASH) Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Non-Alcoholic Steatohepatitis (NASH) Treatment as of 2020)
Table 17. Ranking of Global Top Non-Alcoholic Steatohepatitis (NASH) Treatment Companies by Revenue (US$ Million) in 2020
Table 18. Global 5 Largest Players Market Share by Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue (CR5 and HHI) & (2016-2021)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Non-Alcoholic Steatohepatitis (NASH) Treatment Product Solution and Service
Table 21. Date of Enter into Non-Alcoholic Steatohepatitis (NASH) Treatment Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Type (2016-2021) (US$ Million)
Table 24. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue Market Share by Type (2016-2021)
Table 25. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 26. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 27. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size Share by Application (2016-2021) & (US$ Million)
Table 28. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue Market Share by Application (2016-2021)
Table 29. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 30. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 31. North America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Type (2016-2021) (US$ Million)
Table 32. North America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 33. North America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Application (2016-2021) (US$ Million)
Table 34. North America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 35. North America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 36. North America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 37. Europe Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Type (2016-2021) (US$ Million)
Table 38. Europe Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 39. Europe Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Application (2016-2021) (US$ Million)
Table 40. Europe Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 41. Europe Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 42. Europe Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 43. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Type (2016-2021) (US$ Million)
Table 44. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 45. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Application (2016-2021) (US$ Million)
Table 46. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Region (2016-2021) & (US$ Million)
Table 48. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Region (2022-2027) & (US$ Million)
Table 49. Latin America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Type (2016-2021) (US$ Million)
Table 50. Latin America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 51. Latin America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Application (2016-2021) (US$ Million)
Table 52. Latin America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 53. Latin America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 54. Latin America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 55. Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Type (2016-2021) (US$ Million)
Table 56. Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 57. Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Application (2016-2021) (US$ Million)
Table 58. Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 60. Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 61. Allergan Plc (Tobira) Company Details
Table 62. Allergan Plc (Tobira) Business Overview
Table 63. Allergan Plc (Tobira) Non-Alcoholic Steatohepatitis (NASH) Treatment Product
Table 64. Allergan Plc (Tobira) Revenue in Non-Alcoholic Steatohepatitis (NASH) Treatment Business (2016-2021) & (US$ Million)
Table 65. Allergan Plc (Tobira) Recent Development
Table 66. Bristol Myers Squibb Company Details
Table 67. Bristol Myers Squibb Business Overview
Table 68. Bristol Myers Squibb Non-Alcoholic Steatohepatitis (NASH) Treatment Product
Table 69. Bristol Myers Squibb Revenue in Non-Alcoholic Steatohepatitis (NASH) Treatment Business (2016-2021) & (US$ Million)
Table 70. Bristol Myers Squibb Recent Development
Table 71. Galmed Pharmaceuticals Company Details
Table 72. Galmed Pharmaceuticals Business Overview
Table 73. Galmed Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Treatment Product
Table 74. Galmed Pharmaceuticals Revenue in Non-Alcoholic Steatohepatitis (NASH) Treatment Business (2016-2021) & (US$ Million)
Table 75. Galmed Pharmaceuticals Recent Development
Table 76. Genfit SA Company Details
Table 77. Genfit SA Business Overview
Table 78. Genfit SA Non-Alcoholic Steatohepatitis (NASH) Treatment Product
Table 79. Genfit SA Revenue in Non-Alcoholic Steatohepatitis (NASH) Treatment Business (2016-2021) & (US$ Million)
Table 80. Genfit SA Recent Development
Table 81. Gilead Sciences, Inc. Company Details
Table 82. Gilead Sciences, Inc. Business Overview
Table 83. Gilead Sciences, Inc. Non-Alcoholic Steatohepatitis (NASH) Treatment Product
Table 84. Gilead Sciences, Inc. Revenue in Non-Alcoholic Steatohepatitis (NASH) Treatment Business (2016-2021) & (US$ Million)
Table 85. Gilead Sciences, Inc. Recent Development
Table 86. Intercept Pharmaceuticals, Inc. Company Details
Table 87. Intercept Pharmaceuticals, Inc. Business Overview
Table 88. Intercept Pharmaceuticals, Inc. Non-Alcoholic Steatohepatitis (NASH) Treatment Product
Table 89. Intercept Pharmaceuticals, Inc. Revenue in Non-Alcoholic Steatohepatitis (NASH) Treatment Business (2016-2021) & (US$ Million)
Table 90. Intercept Pharmaceuticals, Inc. Recent Development
Table 91. Zydus Cadila Company Details
Table 92. Zydus Cadila Business Overview
Table 93. Zydus Cadila Non-Alcoholic Steatohepatitis (NASH) Treatment Product
Table 94. Zydus Cadila Revenue in Non-Alcoholic Steatohepatitis (NASH) Treatment Business (2016-2021) & (US$ Million)
Table 95. Zydus Cadila Recent Development
Table 96. Research Programs/Design for This Report
Table 97. Key Data Information from Secondary Sources
Table 98. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market Share by Type: 2020 VS 2027
Figure 2. Off-Label Features
Figure 3. Therapeutic Features
Figure 4. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market Share by Application: 2020 VS 2027
Figure 5. Hospital Pharmacy Case Studies
Figure 6. Online Provider Case Studies
Figure 7. Retail Pharmacy Case Studies
Figure 8. Non-Alcoholic Steatohepatitis (NASH) Treatment Report Years Considered
Figure 9. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 10. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 11. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market Share by Regions: 2020 VS 2027
Figure 12. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market Share by Regions (2022-2027)
Figure 13. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market Share by Players in 2020
Figure 14. Global Top Non-Alcoholic Steatohepatitis (NASH) Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Non-Alcoholic Steatohepatitis (NASH) Treatment as of 2020
Figure 15. The Top 10 and 5 Players Market Share by Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue in 2020
Figure 16. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue Market Share by Type (2016-2021)
Figure 17. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue Market Share by Type (2022-2027)
Figure 18. North America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 19. North America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Share by Type (2016-2027)
Figure 20. North America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Share by Application (2016-2027)
Figure 21. North America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Share by Country (2016-2027)
Figure 22. United States Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 23. Canada Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 24. Europe Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Europe Non-Alcoholic Steatohepatitis (NASH) Treatment Market Share by Type (2016-2027)
Figure 26. Europe Non-Alcoholic Steatohepatitis (NASH) Treatment Market Share by Application (2016-2027)
Figure 27. Europe Non-Alcoholic Steatohepatitis (NASH) Treatment Market Share by Country (2016-2027)
Figure 28. Germany Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 29. France Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. U.K. Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. Italy Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. Russia Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Nordic Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Treatment Market Share by Type (2016-2027)
Figure 36. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Treatment Market Share by Application (2016-2027)
Figure 37. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Treatment Market Share by Region (2016-2027)
Figure 38. China Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 39. Japan Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. South Korea Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. Southeast Asia Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. India Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Australia Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Latin America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Latin America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Share by Type (2016-2027)
Figure 46. Latin America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Share by Application (2016-2027)
Figure 47. Latin America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Share by Country (2016-2027)
Figure 48. Mexico Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 49. Brazil Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Treatment Market Share by Type (2016-2027)
Figure 52. Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Treatment Market Share by Application (2016-2027)
Figure 53. Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Treatment Market Share by Country (2016-2027)
Figure 54. Turkey Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 55. Saudi Arabia Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. UAE Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. Allergan Plc (Tobira) Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Treatment Business (2016-2021)
Figure 58. Bristol Myers Squibb Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Treatment Business (2016-2021)
Figure 59. Galmed Pharmaceuticals Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Treatment Business (2016-2021)
Figure 60. Genfit SA Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Treatment Business (2016-2021)
Figure 61. Gilead Sciences, Inc. Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Treatment Business (2016-2021)
Figure 62. Intercept Pharmaceuticals, Inc. Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Treatment Business (2016-2021)
Figure 63. Zydus Cadila Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Treatment Business (2016-2021)
Figure 64. Bottom-up and Top-down Approaches for This Report
Figure 65. Data Triangulation
Figure 66. Key Executives Interviewed

---